BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.

ABSTRACT:

Background

Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause clinically significant sequelae. Treatment with the use of surgery, radiation, or both is often associated with substantial morbidity related to vision loss, neuroendocrine dysfunction, and memory loss. Genotyping has shown that more than 90% of papillary craniopharyngiomas carry BRAF V600E mutations, but data are lacking with regard to the safety and efficacy of BRAF-MEK inhibition in patients with papillary craniopharyngiomas who have not undergone previous radiation therapy.

Methods

Eligible patients who had papillary craniopharyngiomas that tested positive for BRAF mutations, had not undergone radiation therapy previously, and had measurable disease received th

SUBMITTER: Brastianos PK 

PROVIDER: S-EPMC10464854 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature